Catalyzing biomarker discovery and diagnostics in lung disease
PExA’s non-invasive technology empowers lung disease researchers in healthcare, academia and the pharmaceutical industry to unlock new opportunities for biomarker discovery and improved diagnostics.
Revealing the secrets of the small airways
Changes in the small airways are often the earliest indicators of severe lung diseases. Until now, no accurate, non-invasive methods have been available to collect and analyze material from this critical “silent zone.”
How PexA works
PexA’s non-invasive breath sampling technology enables researchers to collect and analyze Respiratory Tract Lining Fluid (RTLF) from the distal small airways. This fluid contains proteins and lipids that serve as potential biomarkers of lung disease.
Latest press releases
latest news